Zealand Pharma A/S (LON:0NZU)

Zealand Pharma Statistics

Total Valuation

Zealand Pharma has a market cap or net worth of GBP 3.53 billion. The enterprise value is 1.65 billion.

Market Cap	3.53B
Enterprise Value	1.65B

Important Dates

The next estimated earnings date is Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	70.40M
Shares Outstanding	n/a
Shares Change (YoY)	+18.37%
Shares Change (QoQ)	+1.58%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	59.92M

Valuation Ratios

The trailing PE ratio is 4.59.

PE Ratio	4.59
Forward PE	n/a
PS Ratio	3.37
PB Ratio	1.97
P/TBV Ratio	1.97
P/FCF Ratio	4.08
P/OCF Ratio	4.07
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.97, with an EV/FCF ratio of 1.90.

EV / Earnings	2.14
EV / Sales	1.56
EV / EBITDA	1.97
EV / EBIT	1.97
EV / FCF	1.90

Financial Position

The company has a current ratio of 15.09, with a Debt / Equity ratio of 0.03.

Current Ratio	15.09
Quick Ratio	15.08
Debt / Equity	0.03
Debt / EBITDA	0.06
Debt / FCF	0.05
Interest Coverage	224.24

Financial Efficiency

Return on equity (ROE) is 53.44% and return on invested capital (ROIC) is 34.83%.

Return on Equity (ROE)	53.44%
Return on Assets (ROA)	32.86%
Return on Invested Capital (ROIC)	34.83%
Return on Capital Employed (ROCE)	44.76%
Revenue Per Employee	2.47M
Profits Per Employee	1.81M
Employee Count	335
Asset Turnover	0.67
Inventory Turnover	n/a

Taxes

In the past 12 months, Zealand Pharma has paid 61.36 million in taxes.

Income Tax	61.36M
Effective Tax Rate	7.40%

Stock Price Statistics

The stock price has decreased by -53.35% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-53.35%
50-Day Moving Average	387.16
200-Day Moving Average	528.84
Relative Strength Index (RSI)	57.50
Average Volume (20 Days)	20,391

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zealand Pharma had revenue of GBP 1.05 billion and earned 767.70 million in profits. Earnings per share was 10.76.

Revenue	1.05B
Gross Profit	1.05B
Operating Income	825.72M
Pretax Income	829.06M
Net Income	767.70M
EBITDA	826.80M
EBIT	825.72M
Earnings Per Share (EPS)	10.76

Balance Sheet

The company has 1.90 billion in cash and 45.61 million in debt, giving a net cash position of 1.86 billion.

Cash & Cash Equivalents	1.90B
Total Debt	45.61M
Net Cash	1.86B
Net Cash Per Share	n/a
Equity (Book Value)	1.79B
Book Value Per Share	25.48
Working Capital	1.83B

Cash Flow

In the last 12 months, operating cash flow was 866.73 million and capital expenditures -1.64 million, giving a free cash flow of 865.09 million.

Operating Cash Flow	866.73M
Capital Expenditures	-1.64M
Free Cash Flow	865.09M
FCF Per Share	n/a

Margins

Gross margin is 100.06%, with operating and profit margins of 78.88% and 73.34%.

Gross Margin	100.06%
Operating Margin	78.88%
Pretax Margin	79.20%
Profit Margin	73.34%
EBITDA Margin	78.98%
EBIT Margin	78.88%
FCF Margin	82.64%

Dividends & Yields

Zealand Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.37%
Shareholder Yield	n/a
Earnings Yield	21.77%
FCF Yield	24.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zealand Pharma has an Altman Z-Score of 21.97 and a Piotroski F-Score of 6.

Altman Z-Score	21.97
Piotroski F-Score	6